Press release
Lupus Nephritis Pipeline Analysis Covering Clinical Trials, Emerging Therapies, FDA, EMA, and PMDA Approvals, Competitive Landscape | Artiva Biotherapeutics (AlloNK/ AB-101), Roche, Argenx, AstraZeneca, Novartis, Annexon, MorphoSys, Alexion, Cabaletta
"Lupus Nephritis Pipeline Insight" report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Lupus Nephritis Therapeutics Market.
The report provides a detailed description of the Lupus Nephritis drugs, including the mechanism of action, type, stage, route of administration, molecule type, clinical studies, inactive pipeline products, and NDA approvals (if any). The report also covers commercial and clinical activities of the pipeline products from the pre-clinical developmental phase to the marketed stage. Additionally, it presents the ongoing developments in the therapeutics segment, including collaborations, licensing, mergers & acquisitions (M&A), funding, designations, and other product-related details.
Get a Detailed Overview of the Lupus Nephritis Clinical Trial Activities and Regulatory Developments in the domain @
https://www.delveinsight.com/report-store/lupus-nephritis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr
Lupus Nephritis Pipeline Analysis
The report provides insights into:
• The report provides detailed insights into the key companies that are developing Lupus Nephritis therapies.
• The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Lupus Nephritis treatment.
• It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• It navigates the emerging Lupus Nephritis drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement in the Lupus Nephritis treatment market.
Learn More about the Clinical and Commercial Development Activities in the Lupus Nephritis Therapeutics Domain @
https://www.delveinsight.com/report-store/lupus-nephritis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr
Lupus Nephritis Therapeutics Analysis
There are over 20 prominent companies currently engaged in the development of therapies aimed at treating Lupus Nephritis, a condition marked by inflammation of the kidneys caused by systemic lupus erythematosus. Among these companies, Roche stands out for having advanced Lupus Nephritis drug candidates in the most progressed stage of clinical trials, specifically in Phase III. These efforts underscore a collective commitment within the pharmaceutical industry to address the unmet medical needs of individuals grappling with Lupus Nephritis, potentially paving the way for more effective treatment options and improved patient outcomes.
On February 22, 2024, Artiva Biotherapeutics announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to Artiva's lead program AlloNK® (also known as AB-101) for the treatment of lupus nephritis (LN) in combination with rituximab or obinutuzumab. Artiva previously received FDA clearance of an Investigational New Drug (IND) application for AlloNK in combination with rituximab in LN, marking the first IND clearance of an allogeneic, off-the-shelf NK cell therapy in autoimmune disease.
Lupus Nephritis Companies in the Therapeutics Market Include:
Some of the key companies in the Lupus Nephritis Market include Roche, Horizon Therapeutics, Equillium, Argenx, AstraZeneca, Novartis, RemeGen, Annexon, MorphoSys, Kezar Life Sciences, Alexion Pharmaceuticals, Cabaletta Bio, and others.
Emerging and Marketed Lupus Nephritis Therapies Covered in the Report Include:
• Daxdilimab: Horizon Therapeutics
• Itolizumab: Equillium
• Ianalumab (VAY736): Novartis/MorphoSys
• GAZYVA/GAZYVARO (obinutuzumab): Roche
• BENLYSTA (belimumab): GlaxoSmithKline
• LUPKYNIS (voclosporin): Aurinia Pharmaceuticals/Otsuka Pharmaceutical
And Many More
Get an in-depth Assessment of the Emerging Therapies and Lupus Nephritis Companies Actively Working in the Market @
https://www.delveinsight.com/sample-request/lupus-nephritis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr
The Report Covers the Emerging Lupus Nephritis Therapies Under Different Phases of Clinical Development Like -
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued and inactive candidates
Route of Administration
Lupus Nephritis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical
Molecule Type
Products have been categorized under various Molecule types such as
• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy
Request for Sample PDF to Understand More About the Lupus Nephritis Treatment Outlook and Future Perspectives @
https://www.delveinsight.com/sample-request/lupus-nephritis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr
Table of Content
1. Report Introduction
2. Executive Summary
3. Lupus Nephritis Current Treatment Patterns
4. Lupus Nephritis - DelveInsight's Analytical Perspective
5. Therapeutic Assessment
6. Lupus Nephritis Late-Stage Products (Phase-III)
7. Lupus Nephritis Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Lupus Nephritis Discontinued Products
13. Lupus Nephritis Product Profiles
14. Lupus Nephritis Companies
15. Lupus Nephritis Drugs
16. Dormant and Discontinued Products
17. Lupus Nephritis Unmet Needs
18. Lupus Nephritis Future Perspectives
19. Lupus Nephritis Analyst Review
20. Appendix
21. Report Methodology
Get Detailed Insights About the Reports Offerings @
https://www.delveinsight.com/sample-request/lupus-nephritis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr
Contact Info:
Shruti Thakur
Manager - Marketing & International Branding
Email: info@delveinsight.com
428, D21 Corporate Park, Sector-21, Dwarka, New Delhi-110077, India
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Lupus Nephritis Pipeline Analysis Covering Clinical Trials, Emerging Therapies, FDA, EMA, and PMDA Approvals, Competitive Landscape | Artiva Biotherapeutics (AlloNK/ AB-101), Roche, Argenx, AstraZeneca, Novartis, Annexon, MorphoSys, Alexion, Cabaletta here
News-ID: 3407529 • Views: …
More Releases from DelveInsight Business Research LLP
Genital Warts Pipeline Insights Report 2025 | DelveInsight
DelveInsight's, "Genital Warts Pipeline Insight 2025" report provides comprehensive insights about 30+ companies and 30+ pipeline drugs in Genital Warts pipeline landscape. It covers the Genital Warts pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore the comprehensive insights by DelveInsight and stay ahead…
Traumatic Brain Injury Pipeline Drugs Report 2025 | DelveInsight
DelveInsight's "Traumatic Brain Injury Pipeline Insight 2025" report provides comprehensive insights about 20+ companies and 22+ pipeline drugs in Tthe raumatic Brain Injury pipeline landscape. It covers the Traumatic Brain Injury pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Traumatic Brain Injury pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore…
Bone Metastasis Pipeline Assessment Report 2025 | DelveInsight
DelveInsight's, "Bone Metastases Pipeline Insight, 2025," report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Bone Metastases pipeline landscape. It covers the Bone Metastasis pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Bone Metastasis pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore the comprehensive insights by DelveInsight…
Acquired Immunodeficiency Syndrome Treatment Market Size Report 2032 | DelveInsi …
DelveInsight's "Acquired Immunodeficiency Syndrome Market Insights, Epidemiology, and Market Forecast-2032′′ report offers an in-depth understanding of the Acquired Immunodeficiency Syndrome, historical and forecasted epidemiology as well as the Acquired Immunodeficiency Syndrome market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
To Know in detail about the Acquired Immunodeficiency Syndrome market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Acquired Immunodeficiency Syndrome Market…
More Releases for Lupus
Prominent Cutaneous Lupus Erythematosus Market Trend for 2025: Advancements In C …
What combination of drivers is leading to accelerated growth in the cutaneous lupus erythematosus market?
The rising prevalence of skin infections is expected to drive the growth of the cutaneous lupus erythematosus (CLE) market. Skin infections are caused by microorganisms that invade the skin, triggering immune responses that can worsen symptoms in individuals with CLE. For example, the UK saw a 33.7% increase in MRSA cases caused by skin and soft…
Primary Catalyst Driving Lupus Therapeutics Market Evolution in 2025: Rising Res …
"What Is the Future Outlook for the Lupus Therapeutics Market's Size and Growth Rate?
The market size for lupus therapeutics has seen substantial growth in the past few years. It is projected to expand from $2.74 billion in 2024 to $2.99 billion in 2025, exhibiting a compound annual growth rate (CAGR) of 8.9%. The historic growth of this market can be associated with a rise in cases of lupus, increased funding…
Cutaneous Lupus Erythematosus (CLE) Market
Market Overview:
The Global Cutaneous Lupus Erythematosus (CLE) Market is forecasted to achieve a High CAGR during the period 2023-2030. CLE encompasses a spectrum of dermatological symptoms that may precede or accompany systemic lupus erythematosus (SLE), an autoimmune condition impacting multiple organs. Timely diagnosis and treatment of CLE can prevent the onset of severe systemic symptoms.
Market Dynamics:
Drivers:
Rise in Clinical Studies: Technological advancements leading to faster and accurate diagnosis have spurred additional…
Lupus Nephritis Treatment Market 2030
Global Lupus Nephritis Treatment market is expected to be worth roughly USD 8,048 million by 2030, growing at a CAGR of 7.3% during the forthcoming period of 2022-2030, according to Ameco Research
Lupus nephritis is one of the most rapidly spreading diseases over the globe. The increasing frequency of lupus nephritis and consumer awareness has fuelled the worldwide lupus nephritis treatment market. Another crucial factor driving the pace of growth of…
Lupus Erythematosus Market -API Insights, 2017
Summary
Orbis Research Present “Lupus Erythematosus-API Insights, 2017”
Description
The active pharmaceutical ingredients worldwide market is in continuous development from the recent years. There is expected to be a major impact on the global API industry, with the large number of blockbuster drugs going off patent in the coming years. It is going to affect the revenue of the API market as generic drugs occupy the market.
India and China produce a large percentage…
Global Systemic Lupus Erythematosus and Lupus Nephritis Market to Display 10.6% …
"The Report PharmaPoint: Systemic Lupus Erythematosus and Lupus Nephritis - Global Drug Forecast and Market Analysis to 2025 provides information on pricing, market analysis, shares, forecast, and company profiles for key industry participants. - MarketResearchReports.biz"
MarketResearchReports.biz has announced the addition of a new report, titled “PharmaPoint: Systemic Lupus Erythematosus And Lupus Nephritis - Global Drug Forecast And Market Analysis To 2025,” to its expanding repository of research reports. The market…
